Profund Advisors Lowers stake in Incyte Corporation (INCY)

Incyte Corporation (INCY) : Profund Advisors reduced its stake in Incyte Corporation by 4.05% during the most recent quarter end. The investment management company now holds a total of 100,957 shares of Incyte Corporation which is valued at $8,182,565 after selling 4,258 shares in Incyte Corporation , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Incyte Corporation makes up approximately 0.38% of Profund Advisors’s portfolio.

Other Hedge Funds, Including , Mitsubishi Ufj Trust Banking Corp boosted its stake in INCY in the latest quarter, The investment management firm added 748 additional shares and now holds a total of 334,775 shares of Incyte Corporation which is valued at $27,133,514. Incyte Corporation makes up approx 0.06% of Mitsubishi Ufj Trust Banking Corp’s portfolio. Btg Pactual Global Asset Management Ltd sold out all of its stake in INCY during the most recent quarter. The investment firm sold 3,576 shares of INCY which is valued $289,835. Peak6 Investments added INCY to its portfolio by purchasing 2,741 company shares during the most recent quarter which is valued at $222,158. Incyte Corporation makes up approx 0.01% of Peak6 Investments’s portfolio. First Personal Financial Services added INCY to its portfolio by purchasing 432 company shares during the most recent quarter which is valued at $38,033. Incyte Corporation makes up approx 0.01% of First Personal Financial Services’s portfolio. Ngam Advisors added INCY to its portfolio by purchasing 11,851 company shares during the most recent quarter which is valued at $1,076,189. Incyte Corporation makes up approx 0.01% of Ngam Advisors’s portfolio.

Incyte Corporation opened for trading at $81.1 and hit $81.88 on the upside on Monday, eventually ending the session at $81.33, with a gain of 0.36% or 0.29 points. The heightened volatility saw the trading volume jump to 5,91,455 shares. Company has a market cap of $15,290 M.

On the company’s financial health, Incyte Corporation reported $0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.20 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.02. The company had revenue of $246.30 million for the quarter, compared to analysts expectations of $232.33 million. The company’s revenue was up 51.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.

Many Wall Street Analysts have commented on Incyte Corporation. Company shares were Reiterated by Barclays on Aug 10, 2016 to “Overweight”, Firm has raised the Price Target to $ 100 from a previous price target of $85 .Company shares were Reiterated by Leerink Partners on Aug 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 95 from a previous price target of $85 .Incyte Corporation was Initiated by SunTrust to “Buy” on Aug 5, 2016.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f

Leave a Reply

Incyte Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Incyte Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.